[MO-90] Clinical outcome of drug coated balloon(Lutonix) for femoropopliteal artery disease
Purpose:The purpose of this study was to evaluate clinical outcomes of drug coated balloon(Ltonix) for de novo femoropopliteal artery disease.
Methods:A retrospective study was performed of 28 patients(31 lesions) who underwent EVT for femoropopliteal arteries presented from November 2017 to October 2018.
Results:The mean age of the patients was 76±8years old and 29% of the patients were male,46% of the patients had diabetes mellitus,39% were current smoker or former smoker and 21% had critical limbs ischemia.30 lesions (97%) were classified as A/B according to TASCIIclassification.2 lesions(6%) were chronic total occlusion(CTO),mean lesion length was 50mm.Mean lesion length was 89±42mm,mean reference diameter was 5.19±0.48mm and mean DCB number was 1.2.The rate of DCB transit time<30seconds were 100%. Primary patency rate was 100% at the present moment.Event free survival(Freedom from death,stroke,myocardial infarction,major amputation,taget lesion revascularization) rate was 100%.
Conclusion: This study demonstrated favorable outcomes and safety for Lutonix DCB. Further follow up is a necessary to determine the long-term efficacy of these interventions.
Methods:A retrospective study was performed of 28 patients(31 lesions) who underwent EVT for femoropopliteal arteries presented from November 2017 to October 2018.
Results:The mean age of the patients was 76±8years old and 29% of the patients were male,46% of the patients had diabetes mellitus,39% were current smoker or former smoker and 21% had critical limbs ischemia.30 lesions (97%) were classified as A/B according to TASCIIclassification.2 lesions(6%) were chronic total occlusion(CTO),mean lesion length was 50mm.Mean lesion length was 89±42mm,mean reference diameter was 5.19±0.48mm and mean DCB number was 1.2.The rate of DCB transit time<30seconds were 100%. Primary patency rate was 100% at the present moment.Event free survival(Freedom from death,stroke,myocardial infarction,major amputation,taget lesion revascularization) rate was 100%.
Conclusion: This study demonstrated favorable outcomes and safety for Lutonix DCB. Further follow up is a necessary to determine the long-term efficacy of these interventions.